LQDA logo

LQDA Liquidia Corporation

NASDAQ Capital Market · Medical - Pharmaceuticals · Healthcare

$55.99
-0.64 (-1.13%)

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hyperten…

Market Cap: $5.05Bwww.liquidia.com

Price

$71.35
$71.35
Aug 25Aug 25

Social Signal Score

50
5d
—
30d
54
11 mentions
+0.0%
60d
50
28 mentions
+0.0%
90d
47
39 mentions
+1.5%
news: 29 · marketaux: 5 · rss: 5

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 2Sell 1Strong Sell 0
Avg price target$78.18+39.6%
Low $54Median $65High $130
Current Consensus

52-week range

$21.80$91.03
Last close
$71.35
Off 52w high
-21.6%
200-day average
$49.70
vs 200-day
+43.6%

Compare with other stocks off their highs

Revenue

$225.30M+13644.72%
$0.00$75.10M$150.20M$225.30M
Mar 2017Sep 2026

Analyst Estimates

FY2025
$-0.68
$-0.78–$-0.53
4 analysts
FY2026
$-0.13
$-0.27–$-0.04
4 analysts
FY2027
$3.88
$3.02–$5.34
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Roger A. Jeffs
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
216
Beta
0.54
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
3.31
www.liquidia.com